Healthcare services company Agilon Health (NYSE: AGL) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 5.9% year on year to $1.39 billion. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates.

Is now the time to buy AGL? Find out in our full research report (it’s free).

StockStory’s Take

Agilon health’s second quarter was marked by a significant revenue shortfall and a sharply negative market reaction. Management attributed the underperformance to weaker-than-expected risk adjustment revenue and lingering challenges in its Part D business. Executive Chair Ronald Williams described the results as disappointing, emphasizing that both industry headwinds and internal execution gaps contributed to the quarter’s outcome. The leadership transition, with Williams stepping in as Executive Chairman and CEO Steven Sell’s departure, signals an urgent focus on operational improvement and cost discipline as the company navigates a volatile healthcare environment.

Looking forward, management sees 2025 as a transition year, emphasizing initiatives to improve contract economics, enhance data visibility, and strengthen clinical programs. Williams acknowledged, “We have not yet captured the full upside from these enhancements this year, but are confident in realizing them in 2026.” The company is prioritizing negotiations with payer partners, aiming to secure better economic terms and reduce exposure to unpredictable elements like Part D. While growth plans are under review, agilon is betting on operational rigor and a more favorable Medicare reimbursement environment to drive a return to profitability in 2026 and beyond.

Key Insights from Management’s Remarks

Agilon’s management cited risk adjustment underperformance, unfavorable prior period developments, and the need for a culture of urgency as the main reasons for missing expectations and resetting strategy.

• Risk adjustment headwinds: The company’s enhanced data platform revealed that risk adjustment revenue for both 2024 and 2025 was lower than anticipated, due to incomplete identification and documentation of patient conditions. This issue drove much of the revenue and margin shortfall.
• Part D exposure reductions: Management highlighted that negative prior period developments were partly driven by Part D costs. By exiting certain markets and negotiating carve-outs with payers, they expect Part D-related variability to drop significantly in 2026.
• Leadership transition for accountability: Executive Chair Ronald Williams is now leading daily operational reviews as part of an "office of the Chairman" approach. This change reflects a push for faster response times and a heightened level of operational urgency across the organization.
• Platform and data investment: Substantial investment in technology and data platforms now covers 72% of agilon’s patient base, providing better visibility into clinical and financial performance. This is expected to support better forecasting and risk management going forward.
• Quality programs and clinical pathways: Agilon is expanding disease-specific clinical programs, especially in areas like heart failure and advanced illness management, aiming to improve patient outcomes and future quality incentive payments. Early results show reduced hospital admissions and increased enrollment, laying the groundwork for stronger performance in 2026.

Drivers of Future Performance

Management’s outlook is shaped by a focus on contract renegotiation, operational discipline, and the phased impact of recent technology investments.

• Contract economics and payer negotiations: The company is actively renegotiating about 50% of its contracts for 2026, seeking to align economic terms with the value delivered and reduce supplemental benefit risk. Management believes that improved contract terms and a more normalized payer bidding environment are critical for restoring profitability.
• Operational and cost discipline: Agilon is pursuing further reductions in operating expenses and tighter management of medical costs, especially in areas like inpatient care and oncology drugs. Management expects these efforts to improve near-term profitability and set a stronger base for future growth.
• Data-driven care and risk adjustment: Enhanced data capabilities are supporting more accurate risk scoring and early identification of high-risk patients. The company expects these upgrades to drive more reliable revenue and quality performance metrics in 2026, though acknowledges that full benefits will take time to materialize.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory analysts will be monitoring (1) the pace and outcome of contract renewals with payer partners, which will be crucial for 2026 profitability; (2) execution on reducing exposure to Part D and other volatile revenue streams; and (3) tangible improvements in operational efficiency and clinical program expansion. Progress on CEO recruitment and the ability to maintain strong physician partnership retention will also be pivotal for agilon’s turnaround.

agilon health currently trades at $0.90, down from $1.82 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.